Giving your son the chair gives him none of your shares. Ask Kelun
On 18 November 2026 Kelun Pharmaceutical's board voted 9 to 0 to make founder Liu Gexin's son, Liu Sichuan, its chairman. The father kept the 23.83% that makes him the controlling shareholder, about twelve times his son's stake, with 84.63 million shares pledged. In Singapore, three private documents, not the board, would decide who votes that block when he no longer can.
Read this in: EN · 简体 · 繁體 · ไทย · ID

A Chengdu founder grows his infusion maker into three listed firms, vowing in 2016 to hand over at its peak
Liu Gexin founded Kelun in Chengdu in 1996 and built it on intravenous infusions. It listed in Shenzhen in 2010 and has since floated two subsidiaries: Kelun-Biotech, a cancer-drug developer listed in Hong Kong, and the antibiotic-intermediates maker Chuanning Biotech. Kelun holds 52.11% of the first and 72.12% of the second, according to Wind data cited by Shenlan Caijing on 20 November 2026. In 2016 Liu said his aim was to hand over the chair while the company was at its peak and free of outside crisis.
The board votes 9 to 0 in November 2026 to make the founder's son chairman; the father keeps his seat
On 18 November 2026 he did. Kelun's announcement of 19 November says he resigned as chairman, and with it as legal representative. The board, called on 16 November, voted 9 to 0 to elect his son Liu Sichuan, born in 1984, who stays general manager. The father remains a director, heads the board's strategy committee and stays chairman or director of some subsidiaries. The same day Kelun-Biotech made the son chairman of its board, and the father stayed on as a non-executive director.
The son gets the chair but only 1.95% of the shares, while his father keeps 23.83%, twelve times as much
What did not move is the ownership. Kelun's third-quarter report lists Liu Gexin, at 30 September 2026, as the largest shareholder with 379,128,280 shares, 23.83% of 1,590,781,208. Exactly three quarters of them, 284,346,210, are restricted shares, which the company's filings describe as executive lock-up shares, and 84,630,000 are pledged. The son holds 8,346,286 shares directly and 22,650,600 through three private funds managed by Shanghai Tongyi Investment Management: 30,996,886 in all, or 1.95%. The father's block is about twelve times the son's.
The father pledges 8.82 million more shares to a broker in September, and the filings show no family dispute
The pledges are routine and recent. On 2 September 2026 Kelun announced that Liu Gexin had released 12.5 million pledged shares and pledged 8.82 million more to Huatai Securities (Shanghai) Asset Management until August 2027, for what the filing calls personal funding needs. The third-quarter report also names two relatives among the top ten holders, his sister Liu Yaguang with 0.95% and his brother-in-law Yin Fenggang with 0.91%, and says they do not act in concert with him. Nothing in the filings or the coverage suggests any dispute.
- 1Kelun Pharmaceutical (002422.SZ), announcement 2026-087 on the change of chairman, 19 Nov 2026: Liu Gexin's resignation as chairman and legal representative; board vote 9-0 on 18 Nov; Liu Sichuan's résumé (born 1984) and holdings, 8,346,286 shares direct and 22,650,600 through the Tongyi Wutong No. 10, 13 and 20 funds
- 2Kelun Pharmaceutical, resolution of the 17th meeting of the 8th board, announcement 2026-086, 19 Nov 2026: notice served 16 Nov, nine of nine directors present
- 3Kelun Pharmaceutical, 2026 third-quarter report, 29 Oct 2026: top ten shareholders at 30 Sep 2026 (Liu Gexin 379,128,280 shares, 23.83%, 284,346,210 restricted, 84,630,000 pledged; Liu Yaguang 0.95%; Yin Fenggang 0.91%; not acting in concert); share capital 1,590,781,208
- 4Kelun Pharmaceutical, announcement 2026-075 on the controlling shareholder's pledge and release, 2 Sep 2026: 12,500,000 released on 1 Sep; 5,520,000 and 3,300,000 pledged to Huatai Securities (Shanghai) Asset Management from 31 Aug 2026 to Aug 2027, for personal funding needs
- 5Kelun-Biotech (6990.HK), list of directors and their roles, HKEXnews, 18 Nov 2026: Liu Sichuan chairman of the board, Liu Gexin non-executive director
- 6Time Finance via ifeng, 19 Nov 2026: Liu Gexin's 2016 aim to hand over the chair at the company's peak; the son's career at Kelun since 2007
- 7Shenlan Caijing via JRJ, 20 Nov 2026: Liu Gexin born 1951; Kelun's 52.11% of Kelun-Biotech and 72.12% of Chuanning Biotech (Wind data, close of 20 Nov 2026)
- 8Companies Act 1967 s152(1); Mental Capacity Act 2008 ss11(1)-(2), 20(1)-(2); Intestate Succession Act 1967 s7, rules 2 and 3, read on Singapore Statutes Online as at 22 Nov 2026
The board hands the son the job in one meeting, but cannot hand him the votes that elect the board
A board can give a son the job in one meeting. It cannot give him the votes that elect the board. At Kelun the son now chairs both the parent and its Hong Kong-listed subsidiary, but the 23.83% that makes his father the controlling shareholder is still in the father's name. Three quarters of it is locked up while the father sits on the board, and almost a quarter of it is pledged.
A founder born in 1951 stays to watch his son lead, while the plan for his own shares stays private
That is a sensible order for a founder born in 1951 who wants to watch his successor work. It also means the handover is half done. What happens to the block if Liu Gexin can no longer vote it, or when he dies, is set by documents that no announcement mentions, and none of them is public.
In Singapore the son's chair would rest on the same board vote, but who votes his father's 23.83% if the father cannot would be settled by a lasting power of attorney or a court, and who owns it after his death by a will or, without one, by a statutory split among the family.
Singapore shareholders can unseat any public-company director by simple majority, so the chair belongs to whoever votes the big blocks
Start with what would be the same. In Singapore, as in China, the chair is a board appointment, and the board answers to the shareholders: section 152(1) of the Companies Act 1967 lets a public company remove a director by ordinary resolution, whatever its constitution says. So a chairman's seat rests on whoever votes the large blocks. At Kelun that is still the father, which is why last week's handover, however well prepared, settled the job and not the control. The Acts cited here were read on Singapore Statutes Online as at 22 November 2026.
A founder who never signs a lasting power of attorney leaves the votes on 23.83% to a Singapore court application
The first gap is incapacity. Under section 11(1) of the Mental Capacity Act 2008, a lasting power of attorney lets a person name who will make decisions about his property and affairs once he no longer can, and section 11(2)(c) requires him to have capacity on the day he signs it. Without one, section 20 leaves the decision to the court, which may decide itself or appoint a deputy. A Singapore founder in Liu Gexin's position who had not signed one would be leaving the votes on 23.83% of his company to a court application, made on the day it is needed.
Without a will, Singapore gives a founder's widow half his shares and splits the other half among his children
The second gap is death. Singapore has had no estate duty for deaths on or after 15 February 2008, so the block would pass without a tax bill. Where it goes is the question. With a will, it goes where the will says: to the son, to a trust or to a holding company. Without one, the Intestate Succession Act 1967 decides. Under section 7, rule 2, a surviving spouse takes half the estate, and under rule 3 the children share the rest equally.
The controlling block breaks into smaller ones, and the new chairman needs his mother's and siblings' votes to stay
On our reading, that would turn one block that elects a board into several smaller ones, and a new chairman would need his mother's and siblings' votes to keep his seat. The filings say nothing about Liu Gexin's family beyond his son, his sister and his brother-in-law, so this describes the rule, not his household.
Heirs inherit pledged shares with the loan attached, and a lender can sell part of the controlling block
The third item is the pledge. As a general rule, pledged shares carry the loan with them: whoever inherits them takes them subject to the lender's rights, and lenders can usually sell pledged shares if a loan is not repaid. A plan says which assets repay the loan, so that the heir does not have to sell, or watch the lender sell, part of the controlling block.
Chinese law governs Kelun's founder, his shares and his loans, so Singapore's rules here are a comparison, not a verdict
Now the honest limits. Kelun is a Chinese company listed in Shenzhen, and Chinese law governs Liu Gexin's shares, his estate and his pledges; Singapore law reaches none of it. Nothing public says whether he has a will, a trust, a family agreement or an instrument for incapacity, and we do not assume that any is missing. The comparison asks what a Singapore family in the same position would need to have signed.
A finished handover has four parts, and the three that stay private decide whether the new chairman keeps his seat
In Singapore terms, a finished handover has four parts. The chair, by board vote, which Kelun has done. A lasting power of attorney naming who votes the block if the founder cannot. A will, or a trust or holding company set up in his lifetime, saying who owns the block after him. And a written line on how any pledge is repaid. The first is public. The other three are private, and they are the half that decides whether the new chairman keeps his seat.
A reader whose parent made a child the boss checks four things: shares, signatures, the will and any pledge
For the reader whose parent has just made a son or daughter the boss, four questions. Whose name are the shares in today? If your parent were in hospital tomorrow, who could sign for those shares? Is there a will that says who receives them, and does it match the person now running the company? And are any of the shares pledged, and to whom?
Liu Sichuan, the son, born 1984 — chairman of Kelun and of Kelun-Biotech from 18 November 2026, still general manager; 1.95% of Kelun's shares in his own right
Liu Gexin, the founder — a director's seat and the strategy committee; 23.83% of Kelun, 84,630,000 shares of it pledged; in Singapore, the votes until he signs them to someone or a court appoints a deputy
Liu Yaguang and Yin Fenggang, his sister and brother-in-law — 0.95% and 0.91%, which the company says are not voted with his
Kelun's other shareholders, 52,388 holders of record at 30 September 2026 — the same controlling shareholder as before the vote, and no public word on what happens to his block
The reader whose parent has just handed over the job — four questions: whose name the shares are in, who signs if the parent cannot, what the will says, and what is pledged
A counterfactual, not advice. The verified machinery is on the Singapore page; where your family stands is the briefing.
From the case files: Nine days earlier: Nvidia filled Huang's job in a day, but his shares needed their own plan